Avinger Inc.
0.56
-0.04 (-6.73%)
At close: Jan 15, 2025, 10:15 AM

Company Description

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally.

It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.

In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO.

Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee.

It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists.

Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.

Avinger Inc.
Avinger Inc. logo
Country United States
IPO Date Jan 30, 2015
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 71
CEO Himanshu N. Patel

Contact Details

Address:
400 Chesapeake Drive
Redwood City, California
United States
Website https://avinger.com

Stock Details

Ticker Symbol AVGR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001506928
CUSIP Number 053734604
ISIN Number US0537348775
Employer ID 20-8873453
SIC Code 3841

Key Executives

Name Position
Himanshu N. Patel Chief Technology Officer
Keith Schaefer Chief Operating Officer
Dr. Jaafer Golzar FACC, M.D. Chief Medical Officer
Philip R. Preuss Chief Commercial Officer

Latest SEC Filings

Date Type Title
Jan 13, 2025 DEFR14A Filing
Jan 13, 2025 DEFA14A Filing
Jan 03, 2025 8-K Current Report
Jan 02, 2025 8-K Current Report
Dec 23, 2024 DEF 14A Filing
Dec 19, 2024 8-K Current Report
Dec 13, 2024 8-K Current Report
Dec 11, 2024 8-K Current Report
Dec 11, 2024 PRE 14A Filing
Nov 22, 2024 8-K Current Report